1. Home
  2. BDSX vs EPRX Comparison

BDSX vs EPRX Comparison

Compare BDSX & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • EPRX
  • Stock Information
  • Founded
  • BDSX 2005
  • EPRX 2011
  • Country
  • BDSX United States
  • EPRX Canada
  • Employees
  • BDSX N/A
  • EPRX N/A
  • Industry
  • BDSX Precision Instruments
  • EPRX
  • Sector
  • BDSX Health Care
  • EPRX
  • Exchange
  • BDSX Nasdaq
  • EPRX NYSE
  • Market Cap
  • BDSX 115.4M
  • EPRX 137.7M
  • IPO Year
  • BDSX 2020
  • EPRX N/A
  • Fundamental
  • Price
  • BDSX $0.26
  • EPRX $4.32
  • Analyst Decision
  • BDSX Strong Buy
  • EPRX Strong Buy
  • Analyst Count
  • BDSX 5
  • EPRX 1
  • Target Price
  • BDSX $1.75
  • EPRX $9.00
  • AVG Volume (30 Days)
  • BDSX 2.9M
  • EPRX 14.6K
  • Earning Date
  • BDSX 08-06-2025
  • EPRX 08-07-2025
  • Dividend Yield
  • BDSX N/A
  • EPRX N/A
  • EPS Growth
  • BDSX N/A
  • EPRX N/A
  • EPS
  • BDSX N/A
  • EPRX N/A
  • Revenue
  • BDSX $74,463,000.00
  • EPRX N/A
  • Revenue This Year
  • BDSX $17.29
  • EPRX N/A
  • Revenue Next Year
  • BDSX $29.33
  • EPRX N/A
  • P/E Ratio
  • BDSX N/A
  • EPRX N/A
  • Revenue Growth
  • BDSX 35.76
  • EPRX N/A
  • 52 Week Low
  • BDSX $0.17
  • EPRX $2.20
  • 52 Week High
  • BDSX $2.04
  • EPRX $4.49
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 38.93
  • EPRX N/A
  • Support Level
  • BDSX $0.27
  • EPRX N/A
  • Resistance Level
  • BDSX $0.33
  • EPRX N/A
  • Average True Range (ATR)
  • BDSX 0.03
  • EPRX 0.00
  • MACD
  • BDSX 0.01
  • EPRX 0.00
  • Stochastic Oscillator
  • BDSX 19.54
  • EPRX 0.00

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About EPRX EUPRAXIA PHARMACEUTICALS INC

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.

Share on Social Networks: